VRTX · 8-K · 20260803PR000256
CASGEVY Pediatric Market Expansion
VERTEX PHARMACEUTICALS INC / MA · 2026-08-03 · Importance 78 · Surprise 100 · No source text
CASGEVY revenue was $76 million in the second quarter of 2026, up 151% from $30.4 million in the second quarter of 2025 and 78% sequentially. The FDA approved CASGEVY for children aged two and older with sickle cell disease or transfusion-dependent beta thalassemia, making it the first genetic therapy indicated for children as young as two for both diseases. The approval may make approximately 5,500 additional patients eligible for treatment. CASGEVY is approved in 39 countries, and Vertex secured reimbursement for eligible patients aged 12 and older in Germany.
Key facts
- Vertex recorded second quarter 2026 CASGEVY revenue of $76 million, representing 78% quarter-over-quarter sequential growth and 151% growth compared to the second quarter of 2025. source
- The U.S. FDA approved CASGEVY in children 2 years of age and older with SCD or TDT, with approval achieved in 53 days post filing, and approximately 5,500 patients may be eligible for treatment for the first time. source
- In May, Vertex secured reimbursement for CASGEVY for eligible patients 12 years and older with SCD or TDT in Germany. source
- CASGEVY is approved in 39 countries across North America, Europe, and the Middle East. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +1.4% | Vertex recorded second quarter 2026 CASGEVY revenue of $76 million, representing 78% quarter-over-quarter sequential growth and 151%… |
| revenue | positive | probable | — | The U.S. FDA approved CASGEVY in children 2 years of age and older with SCD or TDT, with approval achieved in 53 days post filing, and… |
| revenue | positive | committed | — | In May, Vertex secured reimbursement for CASGEVY for eligible patients 12 years and older with SCD or TDT in Germany. |